|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 803.17 USD | +2.49% |
|
+2.25% | +4.06% |
Sales 2025 by Business Segment
Sales 2025 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Biological Products | ||||||||||
Discovery, Development, and Commercialization of Medicines for Serious Diseases | 1.61TCr | 1.22TCr | 1.31TCr | 1.42TCr | 1.43TCr | |||||
Total Assets | 2.54TCr | 2.92TCr | 3.31TCr | 3.78TCr | 4.06TCr | |||||
Interest Expense | -5.73Cr | -5.94Cr | -7.3Cr | -5.52Cr | -4.38Cr | |||||
Income Tax Expense | 125.05Cr | 52Cr | 25Cr | 37Cr | 73Cr | |||||
CAPEX | -55Cr | -161.69Cr | -72Cr | -76Cr | -90Cr | |||||
EBT | 932.58Cr | 485.88Cr | 419.93Cr | 477.99Cr | 523.07Cr | |||||
D&A | 29Cr | 34Cr | 42Cr | 48Cr | 54Cr | |||||
Operating Income | 894.68Cr | 473.89Cr | 404.71Cr | 399.07Cr | 357.79Cr | |||||
Net Income | 807.53Cr | 433.84Cr | 395.36Cr | 441.26Cr | 450.49Cr |
Geographical Revenue Distribution History
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Rest of World (ROW) | - | - | - | - | - | |||||
United States | - | - | - | - | - | |||||
Total Assets | 268.4Cr | 296Cr | 337.5Cr | 388.4Cr | 433.2Cr | |||||
Total Assets | 80Cr | 80Cr | 77Cr | 72Cr | 79Cr |
- Stock Market
- Equities
- REGN Stock
- Financials Regeneron Pharmaceuticals, Inc.
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition